Pfizer (PFE) Liabilities from Discontinued Operations (2010 - 2019)

Pfizer (PFE) reported Liabilities from Discontinued Operations of 2413000000.0 for Q4 2019, up 27.67% year-over-year from 1890000000.0 in Q4 2018, and up 20.11% quarter-over-quarter from 2009000000.0 in Q2 2019.

Pfizer (PFE) Liabilities from Discontinued Operations (2010 - 2019) Analysis & Trends

Pfizer (PFE) has 6 years of Liabilities from Discontinued Operations data on file, last reported at 2413000000.0 in Q4 2019.

  • Liabilities from Discontinued Operations for Q4 2019 came in at 2413000000.0, up 27.67% year-over-year; the trailing twelve-month figure through Dec 2019 was 2413000000.0 (up 27.67% YoY), and the FY2019 annual result was 2413000000.0, up 27.67% from the prior year.
  • Liabilities from Discontinued Operations rose to 2413000000.0 in Q4 2019 per PFE's latest filing, from 2009000000.0 in the prior quarter.
  • Over five years, Liabilities from Discontinued Operations peaked at 2413000000.0 in Q4 2019 and troughed at 1890000000.0 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2019 2.41 Bn
Dec 31, 2019 2.41 Bn
Jun 30, 2019 2.01 Bn
Jun 30, 2019 2.01 Bn
Mar 31, 2019 1.94 Bn
Mar 31, 2019 1.94 Bn
Dec 31, 2018 1.89 Bn
Dec 31, 2018 1.89 Bn
Dec 31, 2013 21.00 Mn
Dec 31, 2013 21.00 Mn
Sep 29, 2013 21.00 Mn
Sep 29, 2013 21.00 Mn
Jun 30, 2013 21.00 Mn
Jun 30, 2013 21.00 Mn
Dec 31, 2012 1.44 Bn
Dec 31, 2012 1.44 Bn
Sep 30, 2012 1.41 Bn
Sep 30, 2012 1.41 Bn
Jul 1, 2012 1.30 Bn
Jul 1, 2012 1.30 Bn